ArticleGlobal epidemiology2026
Safety profile following mRNA-1273 COVID-19 primary vaccination in healthy adults in Indonesia.
Article in Global epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the safety and benefit-risk profile of mRNA-1273 following the vaccine's authorization and the administration of over one million doses in Indonesia. Design: A retrospective analytical study was conducted to assess adverse events following immunization (AEFI) within 28 days after the latest dose of primary vaccine of mRNA-1273 COVID-19 vaccine. Data collection was conducted on November 3rd - December 31st, 2022 in 18 public health centers and one hospital from five regions in Jakarta, Indonesia. All of the participants' candidates will be contacted by trained interviewers via telephone to answer the questionnaire. Results: A total of 1284 subjects (response rate = 31.05%) were enrolled and interviewed, with 13 drop out subjects. The most common solicited local reactions were local pain, erythema and swelling, meanwhile for systemic systemic reaction was fever. Most solicited and systemic local reactions showed an increase in reported events on days 1-3 after vaccination and rapidly decreasing afterwards. After dose 2 of mRNA-1273 COVID-19 vaccine, local pain, was reported more frequently in females and younger age. There were four serious adverse events (SAE) reported in this study which classified as coincidence. Conclusion: mRNA-1273 COVID-19 vaccination in Indonesia is safe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.